Myocarditis
5 videos · last 6 months shuffled daily, then older videos newest first
▶
11:25 HELIOS-B: Vutrisiran With and Without Tafamidis in ATTR-CM
Yasuhiro Hamatani, MD, PhD, discusses a HELIOS-B analysis in transthyretin amyloid cardiomyopathy finding vutrisiran's effects on mortality and cardiovascular events consistent in direction with or without baseline tafamidis, for JACC.
▶
32:37 Patient-Reported Endpoints in Heart Failure Trials
CardioPod: Heart of the Matter examines the Kansas City Cardiomyopathy Questionnaire and the opportunities and challenges of using patient-reported outcomes as endpoints in heart failure clinical trials.
▶
12:08 Short vs Full KCCQ Questionnaire in Heart Failure
Yasuhiro Hamatani, MD, PhD, discusses his JACC study using TOPCAT, PARAGON-HF, DELIVER and FINEARTS-HF data to test whether the 12-item Kansas City Cardiomyopathy Questionnaire can stand in for the FDA-qualified 23-item version in heart failure.
▶
2:45 ATTRibute-CM: Acoramidis Survival Over 54 Months
Kevin Alexander, MD, and C. Michael Gibson, MD, discuss interim findings from ATTRibute-CM and its open-label extension on survival with acoramidis over 54 months in variant transthyretin amyloid cardiomyopathy, including p.V142I.
▶
3:12 ARCHER Phase II Results: A New Hope For Heart Disease
Cardiol Therapeutics presents results from ARCHER, its global Phase 2 trial in acute myocarditis, which it reports reduced left ventricular mass; there are no FDA-approved treatments for the condition.